Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan

Receptors, Chimeric Antigen T-Lymphocytes Receptors, Antigen, T-Cell chimeric antigen receptor T cell therapy Immunotherapy, Adoptive 3. Good health Cohort Studies tisagenlecleucel Japan manufacturing failure Risk Factors Humans Bendamustine Hydrochloride Lymphoma, Large B-Cell, Diffuse
DOI: 10.1111/bjh.18831 Publication Date: 2023-04-25T12:45:47Z
ABSTRACT
Summary For successful chimeric antigen receptor T (CAR‐T) cell therapy, CAR‐T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for manufacturing failure, we performed a nationwide cohort study in Japan and analysed patients with diffuse large B‐cell lymphoma (DLBCL) who underwent tisagenlecleucel production. We compared clinical between 30 cases that failed (7.4%) those succeeded ( n = 378). Among the failures, proportion of previously treated bendamustine (43.3% vs. 14.8%; p < 0.001) was significantly higher, their platelet counts (12.0 17.0 × 10 4 /μL; 0.01) CD4/CD8 T‐cell ratio (0.30 0.56; peripheral blood at apheresis were lower than group. Multivariate analysis revealed repeated use short washout periods prior (odds [OR], 5.52; 0.013 ≥6 cycles period 3–24 months; OR, 57.09; 0.005 ≥3 <3 months), low (OR, 0.495 per 5 0.022) or ratios (<one third) 3.249; 0.011) increased failure. Manufacturing remains an obstacle therapy DLBCL patients. Avoiding factors, such as administration sufficient washout, risk‐adapted strategies may help optimize
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (33)